quinupristin

quinupristin

 [kwin-u´pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with dalfopristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus; administered intravenously.

quinupristin

/quin·u·pris·tin/ (kwin-u´pris-tin) a semisynthetic antibacterial used in conjunction with dalfopristin against various gram-positive organisms, including vancomycin-resistant Enterococcus faecium.

quinupristin

[kwinu′pris-tin]
a semisynthetic antibacterial effective against a variety of gram-positive organisms. It is used in conjunction with dalfopristin in the treatment of serious bacteremia caused by vancomycin-resistant Enterococcus faecium and complicated skin and skin structure infections caused by Streptococcus pyogenes or methicillin-sensitive Staphylococcus aureus. It is administered intravenously.

quinupristin

See Synercid®.
References in periodicals archive ?
5-8 [micro]g/ mL), tetracycline (1-32 [micro]g/mL), quinupristin (0.
For patients who have recently suffered from infection with vancomycin resistant Enterococcus (VRE) or MRSA, prophylaxis with linzolid, or quinupristin / dalfopristin can be considered.
b) Dalfopristin is combined with quinupristin in the same product.
Treatment of methicillin - resistant Staphylococcus aureus infections with quinupristin - dalfopristin in patients intolerant of or failing prior therapy.
These drugs are streptogamins which contain two component types, A and B, which are represented by dalfoprisitin and quinupristin respectively.
Overall, 12 (50%) of 24 of the VRE samples had high levels of gentamicin resistance, 3 (12%) of 25 were resistant to quinupristin (Synercid), 13 (54%) of 24 were resistant to tetracycline, and 20 (83%) of 24 were resistant to penicillin.
It is a novel, injectable antibiotic made of two molecules: quinupristin and dalfopristin.
Synercid[R] is a medication composed of two components, quinupristin and dalfopristin, and is available as an injectable solution.
All of the Enterococcus faecalis isolates were resistant to Quinupristin & Dalfopristin whereas isolated Enterococcus faecium were sensitive to those antimicrobials.